CIK: 0001802630
Total reported value
$2.5B
Reporting period: 2026-03-31 · Number of holdings: 93
Soleus Capital Management, L.P. disclosed 93 holdings in its latest 13F filing for the period ending 2026-03-31, with total reported value of $2.5B and a quarterly turnover rate of 72.3%.
Browse other institutions with $1B to $10B AUMBrowse other institutions starting with "S"
Soleus Capital Management, L.P.'s disclosed holdings carry a Herfindahl concentration index of 0.038 — mathematically equivalent to about 26 equally-sized positions, well below its 93 actual disclosed holdings. That gap points to a strategy built around a small core of high-conviction bets rather than broad diversification.
Position sizes vary widely across the portfolio (a coefficient of variation of 1.60), with a handful of outsized bets alongside many smaller positions.
No strong tilt toward either adding to existing winners or initiating outsized new positions was observed in the latest reported quarter.
Sector classification currently covers about 45% of this portfolio's disclosed value; the remainder includes holdings (e.g. unmapped tickers, options, or other security types) not yet covered by our sector mapping.
Add KRYS
+22.5% $65.9M
Add UTHR
+212.0% $81.8M
Add PODD
+275.0% $75.4M
Trim DXCM
-89.2% -$77.3M
Add VCEL
+233.6% $54.5M
Add TGTX
+28.4% $40.3M
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | KRYS | Krystal Biotech INC | Stock-Healthcare | 12.06% | +3.50% | +22.53% | |
| 2 | CELC | Celcuity INC | Stock-Other | 5.94% | -0.71% | -28.97% | |
| 3 | TGTX | Tg Therapeutics INC | Stock-Healthcare | 5.42% | +1.97% | +28.35% | |
| 4 | PODD | Insulet CORP | Stock-Healthcare | 4.78% | +3.21% | +275.00% | |
| 5 | NVCR | NovoCure Limited | Stock-Healthcare | 4.63% | — | +23.00% | |
| 6 | UTHR | United Therapeutics CORP | Stock-Healthcare | 4.50% | +3.42% | +211.98% | |
| 7 | PRAX | Praxis Precision Medicines I | Stock-Other | 4.31% | — | -8.94% | |
| 8 | VCEL | Vericel CORP | Stock-Other | 3.32% | +2.31% | +233.65% | |
| 9 | ALKS | Alkermes plc | Stock-Healthcare | 2.82% | +1.46% | +49.04% | |
| 10 | ANIP | Ani Pharmaceuticals INC | Stock-Other | 2.55% | +1.13% | +68.69% | |
| 11 | GMED | Globus Medical INC - A | Stock-Healthcare | 2.55% | -0.31% | -17.76% | |
| 12 | GERN | Geron CORP | Stock-Other | 2.50% | +1.37% | +78.23% | |
| 13 | TWST | Twist Bioscience CORP | Stock-Other | 2.36% | — | -34.12% | |
| 14 | EWTX | Edgewise Therapeutics INC | Stock-Other | 1.85% | +1.02% | +59.33% | |
| 15 | BBNX | Beta Bionics INC | Stock-Other | 1.77% | -1.08% | +71.80% | |
| 16 | ALNY | Alnylam Pharmaceuticals INC | Stock-Healthcare | 1.76% | +0.73% | +88.07% | |
| 17 | SNDX | Syndax Pharmaceuticals INC | Stock-Other | 1.63% | — | -23.15% | |
| 18 | INDV | Indivior Pharmaceuticals INC | Stock-Other | 1.57% | +1.57% | NEW | |
| 19 | NPCE | Neuropace INC | Stock-Other | 1.56% | — | +8.47% | |
| 20 | LIVN | LivaNova PLC | Stock-Other | 1.50% | — | +2.64% | |
| 21 | MIRM | Mirum Pharmaceuticals INC | Stock-Other | 1.50% | -0.17% | -30.21% | |
| 22 | BMRN | Biomarin Pharmaceutical INC | Stock-Healthcare | 1.49% | -1.40% | -50.71% | |
| 23 | PGNY | Progyny INC | Stock-Other | 1.42% | +1.42% | NEW | |
| 24 | INSP | Inspire Medical Systems INC | Stock-Healthcare | 1.20% | — | +92.49% | |
| 25 | FOCL | Edap Tms SA -adr | Stock-Other | 1.10% | — | — | |
| 26 | KNSA | Kiniksa Pharmaceuticals International, plc | Stock-Other | 1.02% | — | -11.18% | |
| 27 | MRK | Merck & Co. INC. | Stock-Healthcare | 0.99% | +0.99% | NEW | |
| 28 | ORGO | Organogenesis Holdings INC | Stock-Other | 0.97% | -0.94% | +1.00% | |
| 29 | NTRA | Natera INC | Stock-Healthcare | 0.96% | +0.79% | +495.00% | |
| 30 | AXGN | Axogen INC | Stock-Other | 0.91% | -0.55% | -43.72% | |
| 31 | PCVX | Vaxcyte INC | Stock-Other | 0.91% | — | -36.70% | |
| 32 | ICLR | ICON Public Limited Company | Stock-Healthcare | 0.86% | +0.86% | NEW | |
| 33 | PHVS | Pharvaris N.V. | Stock-Other | 0.80% | — | — | |
| 34 | CERS | Cerus CORP | Stock-Other | 0.79% | +0.49% | +168.84% | |
| 35 | TRVI | Trevi Therapeutics INC | Stock-Other | 0.78% | +0.36% | +80.00% | |
| 36 | IKT | Inhibikase Therapeutics INC | Stock-Other | 0.74% | — | — | |
| 37 | CNTX | Context Therapeutics INC | Stock-Other | 0.74% | +0.74% | NEW | |
| 38 | VIR | Vir Biotechnology INC | Stock-Other | 0.73% | +0.73% | NEW | |
| 39 | XENE | Xenon Pharmaceuticals INC | Stock-Other | 0.69% | +0.69% | NEW | |
| 40 | TVTX | Travere Therapeutics INC | Stock-Other | 0.66% | +0.66% | NEW | |
| 41 | TNDM | Tandem Diabetes Care INC | Stock-Other | 0.61% | +0.61% | NEW | |
| 42 | NRIX | Nurix Therapeutics INC | Stock-Other | 0.59% | -0.26% | -23.06% | |
| 43 | URGN | UroGen Pharma Ltd. | Stock-Other | 0.53% | +0.40% | +384.67% | |
| 44 | SION | Sionna Therapeutics INC | Stock-Other | 0.48% | — | +9.31% | |
| 45 | CORT | Corcept Therapeutics INC | Stock-Healthcare | 0.47% | +0.47% | NEW | |
| 46 | JBIO | Jade Biosciences INC | Stock-Other | 0.45% | — | — | |
| 47 | VCYT | Veracyte INC | Stock-Other | 0.42% | +0.40% | +3099.12% | |
| 48 | IVVD | Invivyd INC | Stock-Other | 0.41% | -0.29% | — | |
| 49 | CCCC | C4 Therapeutics INC | Stock-Other | 0.41% | — | — | |
| 50 | KIDS | Orthopediatrics CORP | Stock-Other | 0.40% | — | +17.13% |
Performance for Q3 2026
+19.4%
Performance Last 4 Quarters
+91.9%
Based on 83% of reported portfolio value with available pricing
| Period | Holdings | Total value | Stability | Top holdings |
|---|---|---|---|---|
| 2026-03-31 | 93 | $2.5B | 72 | |
| 2025-12-31 | 95 | $2.7B | 83 | |
| 2025-09-30 | 88 | $2.0B | 76 | |
| 2025-06-30 | 95 | $1.5B | 0 | |
| 2025-03-31 | 75 | $1.4B | 100 | |
| 2024-12-31 | 81 | $1.6B | 0 | |
| 2024-09-30 | 87 | $1.3B | 0 | |
| 2024-06-30 | 92 | $1.1B | 0 | |
| 2024-03-31 | 91 | $1.3B | 0 | |
| 2023-12-31 | 73 | $901.2M | 0 | |
| 2023-09-30 | 91 | $1.1B | 0 | |
| 2023-06-30 | 101 | $899.5M | 0 | |
| 2023-03-31 | 77 | $965.7M | 0 | |
| 2022-12-31 | 72 | $697.1M | 0 | |
| 2022-09-30 | 76 | $736.0M | 0 | |
| 2022-06-30 | 72 | $641.0M | 0 | |
| 2022-03-31 | 65 | $775.1M | 0 | |
| 2021-12-31 | 68 | $998.8M | 0 | |
| 2021-09-30 | 72 | $641.7M | 0 | |
| 2021-06-30 | 65 | $650.3M | 92 | |
| 2021-03-31 | 72 | $555.0M | 100 | |
| 2020-12-31 | 65 | $757.9M | 100 | |
| 2020-09-30 | 63 | $188.6M | 89 | |
| 2020-06-30 | 61 | $175.4M | 100 | |
| 2020-03-31 | 48 | $85.9M | 73 | |
| 2019-12-31 | 49 | $103.7M | 0 |
Soleus Capital Management, L.P.'s most significant position changes for 2026-03-31: Sold out: Ss Spdr S&p Biotech ETF (XBI); Sold out: Amicus Therapeutics INC (AM6); New buy: Indivior Pharmaceuticals INC (INDV); New buy: Progyny INC (PGNY); Sold out: Gsk Plc-spon Adr (GSK).
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | KRYS | Krystal Biotech INC | +3.5% | +22.53% | Add |
| 2 | UTHR | United Therapeutics CORP | +3.4% | +211.98% | Add |
| 3 | PODD | Insulet CORP | +3.2% | +275.00% | Add |
| 4 | VCEL | Vericel CORP | +2.3% | +233.65% | Add |
| 5 | TGTX | Tg Therapeutics INC | +2% | +28.35% | Add |
| 6 | ALKS | Alkermes plc | +1.5% | +49.04% | Add |
| 7 | GERN | Geron CORP | +1.4% | +78.23% | Add |
| 8 | ANIP | Ani Pharmaceuticals INC | +1.1% | +68.69% | Add |
| 9 | EWTX | Edgewise Therapeutics INC | +1% | +59.33% | Add |
| 10 | NTRA | Natera INC | +0.8% | +495.00% | Add |
| 11 | ALNY | Alnylam Pharmaceuticals INC | +0.7% | +88.07% | Add |
| 12 | CERS | Cerus CORP | +0.5% | +168.84% | Add |
| 13 | VCYT | Veracyte INC | +0.4% | +3099.12% | Add |
| 14 | URGN | UroGen Pharma Ltd. | +0.4% | +384.67% | Add |
| 15 | TNGX | Tango Therapeutics INC | +0.4% | +4400.00% | Add |
| 16 | TRVI | Trevi Therapeutics INC | +0.4% | +80.00% | Add |
| 17 | MIRM | Mirum Pharmaceuticals INC | -0.2% | -30.21% | Trim |
| 18 | NRIX | Nurix Therapeutics INC | -0.3% | -23.06% | Trim |
| 19 | IVVD | Invivyd INC | -0.3% | — | Unchanged |
| 20 | GMED | Globus Medical INC - A | -0.3% | -17.76% | Trim |
| 21 | RIGL | Rigel Pharmaceuticals INC | -0.5% | -96.67% | Trim |
| 22 | AXGN | Axogen INC | -0.6% | -43.72% | Trim |
| 23 | CELC | Celcuity INC | -0.7% | -28.97% | Trim |
| 24 | IMVT | Immunovant INC | -0.8% | -79.28% | Trim |
| 25 | ARGX | Argenx Se - Adr | -0.9% | -88.97% | Trim |
| 26 | ORGO | Organogenesis Holdings INC | -0.9% | +1.00% | Add |
| 27 | BBNX | Beta Bionics INC | -1.1% | +71.80% | Add |
| 28 | BMRN | Biomarin Pharmaceutical INC | -1.4% | -50.71% | Trim |
| 29 | DXCM | Dexcom INC | -2.8% | -89.21% | Trim |
| 30 | XBI | Ss Spdr S&p Biotech ETF | — | EXIT | Sold out |
| 31 | AM6 | Amicus Therapeutics INC | — | EXIT | Sold out |
| 32 | INDV | Indivior Pharmaceuticals INC | — | NEW | New buy |
| 33 | PGNY | Progyny INC | — | NEW | New buy |
| 34 | GSK | Gsk Plc-spon Adr | — | EXIT | Sold out |
| 35 | RAPT | Rapt Therapeutics INC | — | EXIT | Sold out |
| 36 | NBIX | Neurocrine Biosciences INC | — | EXIT | Sold out |
| 37 | MRK | Merck & Co. INC. | — | NEW | New buy |
| 38 | TFX | Teleflex INC | — | EXIT | Sold out |
| 39 | ICLR | ICON Public Limited Company | — | NEW | New buy |
| 40 | CAPR | Capricor Therapeutics INC | — | EXIT | Sold out |
| 41 | THC | Tenet Healthcare CORP | — | EXIT | Sold out |
| 42 | CNTX | Context Therapeutics INC | — | NEW | New buy |
| 43 | VIR | Vir Biotechnology INC | — | NEW | New buy |
| 44 | XENE | Xenon Pharmaceuticals INC | — | NEW | New buy |
| 45 | TVTX | Travere Therapeutics INC | — | NEW | New buy |
| 46 | TNDM | Tandem Diabetes Care INC | — | NEW | New buy |
| 47 | CORT | Corcept Therapeutics INC | — | NEW | New buy |
| 48 | SOPH | SOPHiA GENETICS SA | — | NEW | New buy |
| 49 | 430 | Terns Pharmaceuticals INC | — | EXIT | Sold out |
| 50 | CDTX | Cidara Therapeutics INC | — | EXIT | Sold out |
| Period | Filed | Type | EDGAR |
|---|---|---|---|
| 2026-03-31 | 2026-05-14 | 13F-HR | View on EDGAR |
| 2025-12-31 | 2026-02-12 | 13F-HR | View on EDGAR |
| 2025-09-30 | 2025-11-14 | 13F-HR | View on EDGAR |
| 2025-06-30 | 2025-08-15 | 13F-HR | View on EDGAR |
| 2025-03-31 | 2025-05-15 | 13F-HR | View on EDGAR |
| 2024-12-31 | 2025-02-14 | 13F-HR | View on EDGAR |
| 2024-09-30 | 2024-11-14 | 13F-HR | View on EDGAR |
| 2024-06-30 | 2024-08-14 | 13F-HR | View on EDGAR |
| 2024-03-31 | 2024-05-15 | 13F-HR | View on EDGAR |
| 2023-12-31 | 2024-02-14 | 13F-HR | View on EDGAR |
| 2023-09-30 | 2023-11-14 | 13F-HR | View on EDGAR |
| 2023-06-30 | 2023-08-14 | 13F-HR | View on EDGAR |
| 2023-03-31 | 2023-05-15 | 13F-HR | View on EDGAR |
| 2022-12-31 | 2023-02-14 | 13F-HR | View on EDGAR |
| 2022-09-30 | 2022-11-14 | 13F-HR | View on EDGAR |
| 2022-06-30 | 2022-08-15 | 13F-HR | View on EDGAR |
| 2022-03-31 | 2022-05-16 | 13F-HR | View on EDGAR |
| 2021-12-31 | 2022-02-14 | 13F-HR | View on EDGAR |
| 2021-09-30 | 2021-11-15 | 13F-HR | View on EDGAR |
| 2021-06-30 | 2021-08-16 | 13F-HR | View on EDGAR |
| 2021-03-31 | 2021-05-17 | 13F-HR | View on EDGAR |
| 2020-12-31 | 2021-04-29 | Amendment | View on EDGAR |
| 2020-12-31 | 2021-02-16 | 13F-HR | View on EDGAR |
| 2020-09-30 | 2020-11-13 | 13F-HR | View on EDGAR |
| 2020-06-30 | 2020-08-14 | 13F-HR | View on EDGAR |
| 2020-03-31 | 2020-05-15 | 13F-HR | View on EDGAR |
| 2019-12-31 | 2020-02-14 | 13F-HR | View on EDGAR |
Institutions with a similar AUM
CIK 0001698283
Total reported value
$2.5B
967 stks
2021-06-30
Stale — no recent filing
AUM within 0.1% of this institution
CIK 0001934415
Total reported value
$2.5B
150 stks
2026-03-31
AUM within 0.3% of this institution
CIK 0001879371
Total reported value
$2.5B
259 stks
2026-03-31
AUM within 0.3% of this institution
Institutions with overlapping top holdings
CIK 0001442273
Total reported value
$127.2M
56 stks
2026-03-31
3 of the top 5 holdings overlap, including Krystal Biotech INC
CIK 0000078003
Total reported value
$238.8M
21 stks
2026-03-31
1 of the top 5 holdings overlap, including Celcuity INC
CIK 0000884306
Total reported value
$54.4M
45 stks
2019-09-30
Stale — no recent filing
1 of the top 5 holdings overlap, including Insulet CORP